{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:16:01Z","timestamp":1793924161808,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RM1NS132996"],"award-info":[{"award-number":["RM1NS132996"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG066823"],"award-info":[{"award-number":["R01AG066823"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG077627"],"award-info":[{"award-number":["R01AG077627"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tjpad.2026.100604","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:39:50Z","timestamp":1779194390000},"page":"100604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and biological relevance of objectively-defined subtle cognitive decline in Alzheimer\u2019s disease: a narrative review of neuroimaging, biomarker, and clinical progression studies"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5172-0427","authenticated-orcid":false,"given":"Amanda I.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo E.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Averi","family":"Giudicessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9660-8341","authenticated-orcid":false,"given":"Catarina","family":"Trist\u00e3o-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-9220","authenticated-orcid":false,"given":"Vincent","family":"Malotaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-8244","authenticated-orcid":false,"given":"Yakeel T.","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0001","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the national institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100604_bib0002","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/jpm15090437","article-title":"Anti-amyloid monoclonal antibodies for alzheimer\u2019s disease: evidence, aria risk, and precision patient selection","volume":"15","author":"Alkhalifa","year":"2025","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100604_bib0004","doi-asserted-by":"crossref","unstructured":"Thomas, K.R., Bangen, K.J., Edmonds, E.C., Weigand, A.J., Walker, K.S., Bondi, M.W., et al. Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer\u2019s disease-related declines. Alzheimers Dement Diagn Assess Dis Monit. 2021;13(1):e12238. doi:10.1002\/dad2.12238.","DOI":"10.1002\/dad2.12238"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100604_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008838","article-title":"Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration","volume":"94","author":"Thomas","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100604_bib0006","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0271678X20935171","article-title":"Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline","volume":"41","author":"Thomas","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-180229","article-title":"Alzheimer\u2019s disease neuroimaging initiative. Using neuropsychological process scores to identify subtle cognitive decline and predict progression to mild cognitive impairment","volume":"64","author":"Thomas","year":"2018","journal-title":"J Alzheimer 19s Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100604_bib0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/neu0000413","article-title":"Word-list intrusion errors predict progression to mild cognitive impairment","volume":"32","author":"Thomas","year":"2018","journal-title":"Neuropsychology"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100604_bib0009","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","article-title":"Quantification of five neuropsychological approaches to defining mild cognitive impairment","volume":"17","author":"Jak","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-150128","article-title":"Subtle cognitive decline and biomarker staging in preclinical Alzheimer\u2019s disease","volume":"47","author":"Edmonds","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/WAD.0000000000000332","article-title":"Type 2 diabetes interacts with alzheimer disease risk factors to predict functional decline","volume":"34","author":"Thomas","year":"2020","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100604_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2026.100604_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2022.06.002","article-title":"Increased regional white matter hyperintensity volume in objectively-defined subtle cognitive decline and mild cognitive impairment","volume":"118","author":"Calcetas","year":"2022","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.tjpad.2026.100604_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.684918","article-title":"Local functional MR change pattern and its association with cognitive function in objectively-defined subtle cognitive decline","volume":"13","author":"Cui","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2026.100604_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2023.01.004","article-title":"Brain functional alterations and association with cognition in people with preclinical subjective cognitive decline and objective subtle cognitive difficulties","volume":"513","author":"Ren","year":"2023","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13195-022-01060-1","article-title":"Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint","volume":"14","author":"Thomas","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100604_bib0017","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1111\/ejn.15860","article-title":"Altered functional connectivity pattern of hippocampal subfields in individuals with objectively-defined subtle cognitive decline and its association with cognition and cerebrospinal fluid biomarkers","volume":"56","author":"Qiu","year":"2022","journal-title":"Eur J Neurosci"},{"issue":"5580","key":"10.1016\/j.tjpad.2026.100604_bib0018","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100604_bib0019","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100604_bib0020","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archneurol.2012.1527","article-title":"Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community","volume":"69","author":"Brickman","year":"2012","journal-title":"Arch Neurol"},{"issue":"s4","key":"10.1016\/j.tjpad.2026.100604_bib0021","doi-asserted-by":"crossref","first-page":"S411","DOI":"10.3233\/JAD-141467","article-title":"Cerebral blood flow measured by arterial spin labeling mri as a preclinical marker of Alzheimer\u2019s disease. De La Torre JC, editor","volume":"42","author":"Wierenga","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100604_bib0022","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neurobiolaging.2019.10.016","article-title":"Pattern of regional white matter hyperintensity volume in mild cognitive impairment subtypes and associations with decline in daily functioning","volume":"86","author":"Bangen","year":"2020","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100604_bib0023","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24647","article-title":"White matter hyperintensities are a core feature of Alzheimer\u2019s disease: Evidence from the dominantly inherited Alzheimer network","volume":"79","author":"Lee","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tjpad.2026.100604_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.107025","article-title":"The mediation effects of white matter microstructural abnormalities on the associations between cerebral small vessel disease burden and cognitive impairment","volume":"214","author":"Sui","year":"2025","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100604_bib0025","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.3390\/ijms26094308","article-title":"Assessment of plasma and cerebrospinal fluid biomarkers in patients with alzheimer\u2019s disease and other dementias: a center-based study","volume":"26","author":"De Rino","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1037\/neu0000981","article-title":"Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment","volume":"39","author":"Gonzalez","year":"2025","journal-title":"Neuropsychology"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100604_bib0027","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/cns.13962","article-title":"Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients","volume":"28","author":"Huang","year":"2022","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100604_bib0028","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/alz.12324","article-title":"Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI","volume":"17","author":"Bangen","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100604_bib0029","article-title":"Correlation between urine formaldehyde and cognitive abilities in the clinical spectrum of Alzheimer\u2019s disease","volume":"14","author":"Wang","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acn3.51695","article-title":"Plasma phosphorylated tau181 predicts cognitive and functional decline","volume":"10","author":"Tropea","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100604_bib0031","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/acn3.51553","article-title":"Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease","volume":"9","author":"De Meyer","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100604_bib0032","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.tjpad.2026.100604_bib0033","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","article-title":"Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment","volume":"68","author":"Scheff","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.56.1.127","article-title":"Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease","volume":"56","author":"Masliah","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100604_bib0036","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s007020070088","article-title":"Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer\u2019s disease: an immunohistochemical and quantitative study","volume":"107","author":"Bogdanovic","year":"2000","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0037","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.neuroscience.2004.03.060","article-title":"Subfield-specific increase in brain growth protein in postmortem hippocampus of Alzheimer\u2019s patients","volume":"126","author":"Rekart","year":"2004","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115382","article-title":"Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation","volume":"44","author":"Kahn","year":"2025","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100604_bib0039","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100604_bib0040","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","article-title":"Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment","volume":"269","author":"Giacomucci","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0041","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in Neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0042","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/1354750X.2014.994036","article-title":"Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer\u2019s disease in patients with the apolipoprotein E \u03b54 genotype","volume":"20","author":"Wang","year":"2015","journal-title":"Biomarkers"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0044","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-160357","article-title":"Urine formaldehyde predicts cognitive impairment in post-stroke dementia and Alzheimer\u2019s disease","volume":"55","author":"Tong","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0045","doi-asserted-by":"crossref","DOI":"10.1515\/cclm.2011.792","article-title":"Urinary 8-hydroxy-2\u2032-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer\u2019s disease","volume":"50","author":"Zengi","year":"2012","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0046","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-025-01719-5","article-title":"Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform","volume":"17","author":"Mart\u00ednez-Dubarbie","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0047","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/A\u03b21-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer\u2019s disease","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100604_bib0048","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1002\/alz.14178","article-title":"Significance of plasma p-tau217 in predicting long-term dementia risk in older community residents: Insights from machine learning approaches","volume":"20","author":"Xiao","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100604_bib0049","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/JGP.0b013e3182107c69","article-title":"Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates","volume":"19","author":"Duara","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100604_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.603974","article-title":"Clinical and objective cognitive measures for the diagnosis of cognitive frailty subtypes: a comparative study","volume":"12","author":"Ruan","year":"2021","journal-title":"Front Psychol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100604_bib0051","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/01.wnl.0000228231.26111.6e","article-title":"Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI","volume":"67","author":"Storandt","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100604_bib0052","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213536","article-title":"Objective criteria for subtle cognitive decline in aging and preclinical alzheimer disease: a systematic review","volume":"104","author":"Thomas","year":"2025","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100604_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3019","article-title":"Correlation between ankle-brachial index and subtle cognitive decline","volume":"13","author":"Guo","year":"2023","journal-title":"Brain Behav"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100604_bib0054","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1567205017666200807193253","article-title":"A conceptual framework for research on cognitive impairment with no dementia in memory clinic","volume":"17","author":"Huang","year":"2020","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100604_bib0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12883-020-01657-9","article-title":"A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline","volume":"20","author":"Pan","year":"2020","journal-title":"BMC Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:53:18Z","timestamp":1789487598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2274580726001299"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100604","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biological relevance of objectively-defined subtle cognitive decline in Alzheimer\u2019s disease: a narrative review of neuroimaging, biomarker, and clinical progression studies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100604"}}